BRIEF published on 06/13/2024 at 11:20, 1 year 5 months ago Dr Ingo Mantzke Resigns as Chairman of Swiss Merchant Group AG Advisory Board Resignation Advisory Board Dr. Ingo Mantzke Swiss Merchant Group AG PeopleNet Capital GmbH
BRIEF published on 06/13/2024 at 11:20, 1 year 5 months ago Ingo Mantzke démissionne de son poste de président du conseil consultatif de Swiss Merchant Group AG Démission Conseil Consultatif PeopleNet Capital GmbH Dr Ingo Mantzke Swiss Merchant Group SA
PRESS RELEASE published on 06/13/2024 at 11:15, 1 year 5 months ago Dr Ingo Mantzke has resigned as Chairman of the Advisory Board of Swiss Merchant Group AG Dr. Ingo Mantzke resigns as Chairman of the Advisory Board of Swiss Merchant Group AG. PeopleNet Capital GmbH's Owner/CEO steps down from the mandate effective April 30, 2024 Resignation Advisory Board Dr. Ingo Mantzke Swiss Merchant Group AG PeopleNet Capital GmbH
Published on 12/05/2025 at 02:35, 4 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 26 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 11 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 12 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 27 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 42 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
